We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ - Free Report) , Barclays (BCS - Free Report) , and Procter & Gamble (PG - Free Report) .
Johnson & Johnson shares were up +14.6% last year, widely outperforming the large-cap pharma space (down -3.8%) as well as the S&P 500 index (up +12.1%). While the company is faced with a number of headwinds like unfavorable currency movements, increased competition from generics, pricing pressures and an uncertain global macroeconomic backdrop, the analyst believes that JNJ's diversified business model, deep product pipeline, lack of cyclicality and financial strength position it for continued momentum going forward. We saw this in the company's Q3 earnings report when it beat on the top- and bottom-lines and provided favorable outlook. The analyst expects these trends to continue in the coming periods as well; JNJ is scheduled to report 2016 Q4 results on January 24th. (You can read the full research report on Johnson & Johnson here >>)
Barclays shares have struggled for a while, but the British banking giant appears to have a turned the corner lately, with the stock outperforming the Zacks Foreign Banks industry over the past three months. The analyst thinks that this Zacks Rank #1 (Strong Buy) bank is on track to achieve targeted cost savings this year, driven by continued divestiture of non-core operations world-wide. These are expected to improve operational efficiency and lower expenses, thereby leading to improved profitability over time. Further, Moody’s long term ratings upgrade enhances investors’ confidence in the stock. (You can read the full research report on Barclays here >>)
Procter & Gamble shares were up +8.5% last year, outperforming the Zacks Consumer Staples sector (+4.1%). The analyst likes the company's strong organic sales, which grew 3% in Q3, the best performance in over two years. Productivity improvements and aggressive cost-saving efforts have consistently improved margins with the trend expected to continue going forward. On the flip side, the Zacks analyst points to mature end markets and the negative impact of the strong U.S. dollar as some of the headwinds for the stock. The company is expected to report Q4 results on January 24th, with the current Zacks Consensus EPS of $1.07 on $16.8 billion in revenues. (You can read the full research report on Procter & Gamble here >>)
Free Access: All Zacks Research Reports Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weeklyEarnings TrendsandEarnings Previewreports. If you want an email notification each time Sheraz publishes a new article, pleaseclick here >>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for J&J, Barclays and P&G
Thursday, January 5 2017
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ - Free Report) , Barclays (BCS - Free Report) , and Procter & Gamble (PG - Free Report) .
Johnson & Johnson shares were up +14.6% last year, widely outperforming the large-cap pharma space (down -3.8%) as well as the S&P 500 index (up +12.1%). While the company is faced with a number of headwinds like unfavorable currency movements, increased competition from generics, pricing pressures and an uncertain global macroeconomic backdrop, the analyst believes that JNJ's diversified business model, deep product pipeline, lack of cyclicality and financial strength position it for continued momentum going forward. We saw this in the company's Q3 earnings report when it beat on the top- and bottom-lines and provided favorable outlook. The analyst expects these trends to continue in the coming periods as well; JNJ is scheduled to report 2016 Q4 results on January 24th. (You can read the full research report on Johnson & Johnson here >>)
Barclays shares have struggled for a while, but the British banking giant appears to have a turned the corner lately, with the stock outperforming the Zacks Foreign Banks industry over the past three months. The analyst thinks that this Zacks Rank #1 (Strong Buy) bank is on track to achieve targeted cost savings this year, driven by continued divestiture of non-core operations world-wide. These are expected to improve operational efficiency and lower expenses, thereby leading to improved profitability over time. Further, Moody’s long term ratings upgrade enhances investors’ confidence in the stock. (You can read the full research report on Barclays here >>)
Procter & Gamble shares were up +8.5% last year, outperforming the Zacks Consumer Staples sector (+4.1%). The analyst likes the company's strong organic sales, which grew 3% in Q3, the best performance in over two years. Productivity improvements and aggressive cost-saving efforts have consistently improved margins with the trend expected to continue going forward. On the flip side, the Zacks analyst points to mature end markets and the negative impact of the strong U.S. dollar as some of the headwinds for the stock. The company is expected to report Q4 results on January 24th, with the current Zacks Consensus EPS of $1.07 on $16.8 billion in revenues. (You can read the full research report on Procter & Gamble here >>)
Other noteworthy reports we are featuring today include eBay (EBAY - Free Report) , Kellogg (K - Free Report) and Medtronic (MDT - Free Report) .
Free Access: All Zacks Research Reports
Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>